PolyPid Ltd (NAS:PYPD)

Q3 2025 PolyPid Ltd Earnings Call Transcript

Nov 12, 2025 / 01:30 PM GMT

Release Date Price: $3.75 (-0.27%)

Transcript

Key Points

Positve

PolyPid Ltd (PYPD) is on track to submit the NDA for DPLEX 100 in early 2026, leveraging its fast track and breakthrough therapy designations.
The company successfully completed the Israeli Ministry of Health GMP inspection, marking its fourth consecutive successful inspection, which is crucial for commercial manufacturing readiness.
A new US market access study showed strong interest from surgeons and hospital pharmacy directors, validating the commercial potential of DPLEX 100.
PolyPid Ltd (PYPD) has made significant progress in strategic discussions with potential US partners, building on positive phase 3 trial results.
The company has reduced its debt significantly, decreasing current maturities from $6.5 million to $2.4 million, and expects its cash balance to fund operations well into 2026.

Negative

Research and development expenses remain high, totaling $17.6 million for the nine months ended September 30, 2025, compared to $15.8 million in the prior year period.
General and administrative expenses increased to $5.4 million from $3.3 million last year, indicating rising operational costs.
The net loss for the nine-month period was $25.7 million, an increase from $20.5 million in the same period in 2024.
There are ongoing risks and uncertainties related to regulatory approvals and market adoption, which could impact future results.
The company faces potential challenges related to US domestic manufacturing trends, which could affect the commercialization of DPLEX 100 in the US.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PYPD.OQ - PolyPid Ltd
Q3 2025 PolyPid Ltd Earnings Call
Nov 12, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to Polype's 3rd quarter 2025 conference call. At this time, participants are in a listen-only mode. As a reminder, this call is recorded, and I would now like to introduce your host for today's conference, Ya Leer from Arcs Investor Relations. Mr. Liebler, you may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you all for participating in Polyfid's 3rd quarter 2025 earnings conference call. Joining me on the call today will be Declanchatkis Axelbal, Chief Executive Officer of PolyPd, Johnny Misalawin, Polypid's Chief Financial Officer, and Uri Warshavsky, Chief

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.